According to reports, after the second phase of clinical trials of the new coronavirus in the United States, the production of an antiviral drug Avigan from Japan is accelerating. Avigan is currently undergoing tests to treat new coronavirus. This drug produced by Fujifilm is also called favipiravir. In fact, since 2014, this drug has been approved for production and sale in Japan, when it was used to fight the flu.

The company recently announced that it will allocate the additional capacity of a factory in Japan to generate Avigan as part of the expanded production of medicines. In addition, the company has completed a number of raw materials and necessary medicines with international companies. transaction.

It is reported that Fujifilm’s announced plan is to increase Avignan’s monthly output to 100,000 treatment courses by July, a 2.5-fold increase from March’s output. On this basis, Fujifilm also plans to increase to 300,000 courses by September. By the way, according to Fujifilm, a course requires two doses of 1800 mg of medicine on the first day and two doses of 800 mg of medicine on the second to fourteenth days.

As part of the emergency response to the new coronary pneumonia announced by the Japanese government earlier this month, the company will reserve 2 million Avigan sessions for the Japanese government. Although Fujifilm strives to ensure that the Japanese government has sufficient doses, the company said that they will also contact other countries after consulting with the Japanese government.

Earlier this month, Avigan conducted a new clinical trial in the United States, with about 50 patients with new coronary pneumonia participating in the trial. According to Fujifilm, the trial was conducted in collaboration with Brigham and Women’s Hospital, Massachusetts General Hospital and Massachusetts University School of Medicine.